Pregnancy diagnostics company Sera Prognostics and market research company Fors Marsh announced Tuesday that Fors Marsh will offer Sera’s PreTRM Test in its maternity benefits package.
PreTRM is a blood-based test developed and initially validated as part of the Proteomic Assessment of Preterm Risk (PAPR) study. The test provides early risk assessment for spontaneous preterm birth in asymptomatic, singleton pregnancies.
According to Sera, the test has been validated in multiple studies to identify nearly 90% of pregnancies where spontaneous preterm deliveries will occur. Analysis of the test has also shown that its use in a test-and-treat strategy predicts better neonatal and maternal outcomes, the firm said.
Preterm birth is a leading cause of death in newborns and carries serious risks and complications for both mothers and infants.
“We are encouraged by the PreTRM Test’s ability to help reduce the negative health and cost outcomes associated with preterm birth,” Fors Marsh People and Culture Director Christina Daugherty said in a statement.